New laboratory studies suggest that BioBlock® nasal spray provides protection against all major variants of coronaviruses
New laboratory studies with BioBlock® nasal spray suggest that
BioBlock works against all major variants of coronaviruses, which
the World Health Organization considers to be of most concern. Including the Delta
variant, which is currently widespread in
Estonia.
Read more ›
Icosagen's SARS-CoV-2 Neutralizing Antibody ELISA Kit Is Available for Evaluating Immune Responses to COVID-19 and Carries an IVD CE Mark
Icosagen's SARS-CoV-2 Neutralizing Antibody ELISA Kit Is Available for
Evaluating Immune Responses to COVID-19 and Carries an IVD CE Mark
The SARS-CoV-2 neutralizing antibody ELISA test
provides a qualitative in vitro determination of neutralizing antibodies
of SARS-CoV-2 in human serum or plasma to either characterize obtained
protective condition from previous encounter with the virus or the developed
immune response after vaccination.
Because it is possible that Covid-19 disease
and SARS-CoV-2 vaccines may induce antiviral immunity only for a limited period
of time, the SARS-CoV-2 Neutralizing Antibody ELISA kit allows to determine the
duration and efficacy of antibody immunity. In addition, the test allows
medical facilities to select highly neutralizing blood serums of patients who
have recovered from COVID-19 disease, which then can be used to treat
critically ill patients.
Icosagen's SARS-CoV-2 Neutralizing Antibody
ELISA kit has already played a key role in the development of our BioBlock®
nasal spray, which has been developed in collaboration with Estonian
researchers and entrepreneurs. BioBlock® is a natural formulation derived from
bovine colostrum and contains bovine antibodies to SARS-CoV-2 virus. The
current ELISA test will be further developed to detect the presence of
protective antibodies against other rapidly spreading and severe SARS-CoV-2
strains, such as the UK (B.1.1.7), South African (B.1.351), Brazilian (P.1) and
Indian variants.
Recent studies have shown that antibodies to
common virus strains currently present in Europe offer less protection against
newer strains, especially to Brazilian and South African variants. Thus, from
the vaccination strategy and epidemiological point of view, it is important to
know which strains the Estonian population have protection and which strains
have carry a higher risk of disease.
Icosagen
Cell Factory OÜ's SARS-CoV-2 Neutralizing Antibody ELISA kit was registered on 16 April 2021. With this, Icosagen has
already launched another complete CE-IVD product (CE-marked in vitro diagnostic
medical device) in Estonia.
The test is intended for professional use only,
as laboratory training personnel and special laboratory equipment are required.
The development of diagnostics was supported by the Government of Estonia with €100,000
grant.
Read more ›
BioBlock®, a Novel Prophylactic Nasal Spray With Antibodies Against SARS-CoV-2 Developed by Icosagen, Has Received Marketing Authorization and Is Available for Sale in Estonia
BioBlock® nasal spray is designed to serve as
a prophylactic, supplemental measure to help prevent the spread of the
SARS-CoV-2 virus, reduce the infection rate, and avoid extensive restrictions.
It is intended be used in conjunction with other preventive measures such as masks,
hand hygiene, social distancing, as well as vaccination.
BioBlock® is a natural product derived from
bovine colostrum collected from cows hyperimmunized with the SARS-CoV-2 viral
spike protein. Bovine colostrum is milk produced by cows within the first few
days after giving birth that contains antibodies that provide passive immunity
to the newborn calves. BioBlock® is produced from colostrum that, along with other
naturally occurring beneficial antibodies, contains antibodies against
SARS-CoV-2.
Read more ›
Happy holidays
All of us at Icosagen wish you a very Happy Holiday Season and a Successful New Year!
Read more ›
Estonian Biotech Icosagen Has Developed Highly Potent Next-Generation Therapeutic and Preventative Anti-SARS-CoV-2 Neutralizing Antibodies as Promising Drug Candidates for Covid-19
On
October 12, 2020, the U.S. Patent Office received and registered Icosagen Cell
Factory OÜ’s Patent Application No. 63090576 “SARS-CoV-2 Neutralizing
Antibodies."
Read more ›
KTH protein production with QMCF
KTH produced almost 1300 human secreted recombinant proteins using Icosagen’s QMCF platform within the Human Secretome project https://www.sciencedirect.com/science/article/pii/S1871678420301321
Read more ›
Icosagen's COVID-19 antibody ELISA test is available for diagnostics with an IVD CE mark
Press release: Icosagen Cell Factory was awarded EUR 1.2 million
HybriFree recombinant antibody development article is published
Icosagen AS has incorporated a US subsidiary – Icosagen Technologies, Inc.
The Icosagen Cell Factory OÜ team is looking for a MARKETING SPECIALIST
QMCF Technology to be presented at the CHI's 14th Annual PepTalk conference in San Diego, California
Icosagen Cell Factory was titled the Best Entrepreneur of 2013
Icosagen Cell Factory presentation at Cell Line Development Conference